Clinical Trials
3 trialsNCT03835819 2026-06-01
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03832361 2025-07-18
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Yale University
Phase 2 Recruiting
NCT03836157 2019-06-27
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
University of Oklahoma
Phase 2 Withdrawn